27598262|t|Macular Ganglion Cell - Inner Plexiform Layer Thickness Is Associated with Clinical Progression in Mild Cognitive Impairment and Alzheimers Disease
27598262|a|We investigated the association of the macular ganglion cell - inner plexiform layer (GCIPL) and peripapillary retinal nerve fiber layer (RNFL) thicknesses with disease progression in mild cognitive impairment (MCI) and Alzheimer's disease (AD). We recruited 42 patients with AD, 26 with MCI, and 66 normal elderly controls. The thicknesses of the RNFL and GCIPL were measured via spectral-domain optic coherent tomography in all participants at baseline. The patients with MCI or AD underwent clinical and neuropsychological tests at baseline and once every year thereafter for 2 years. The Clinical Dementia Rating scale-Sum of Boxes (CDR-SB) score exhibited significant negative relationships with the average GCIPL thickness (β = -0.15, p < 0.05) and the GCIPL thickness in the superotemporal, superonasal, and inferonasal sectors. The composite memory score exhibited significant positive associations with the average GCIPL thickness and the GCIPL thickness in the superotemporal, inferonasal, and inferotemporal sectors. The temporal RNFL thickness, the average and minimum GCIPL thicknesses, and the GCIPL thickness in the inferonasal, inferior, and inferotemporal sectors at baseline were significantly reduced in MCI patients who were converted to AD compared to stable MCI patients. The change of CDR-SB from baseline to 2 years exhibited significant negative associations with the average (β = -0.150, p = 0.006) and minimum GCIPL thicknesses as well as GCIPL thickness in the superotemporal, superior, superonasal, and inferonasal sectors at baseline. Our data suggest that macular GCIPL thickness represents a promising biomarker for monitoring the progression of MCI and AD.
27598262	0	7	Macular	T082	C0332574
27598262	8	21	Ganglion Cell	T025	C0228071
27598262	24	45	Inner Plexiform Layer	T023	C1512785
27598262	46	55	Thickness	T080	C1280412
27598262	59	74	Associated with	T080	C0332281
27598262	75	95	Clinical Progression	T046	C0242656
27598262	99	124	Mild Cognitive Impairment	T047	C1719378
27598262	129	147	Alzheimers Disease	T047	C0002395
27598262	187	194	macular	T082	C0332574
27598262	195	208	ganglion cell	T025	C0228071
27598262	211	232	inner plexiform layer	T023	C1512785
27598262	234	239	GCIPL	T023	C1512785
27598262	245	284	peripapillary retinal nerve fiber layer	T023	C1517753
27598262	286	290	RNFL	T023	C1517753
27598262	292	303	thicknesses	T080	C1280412
27598262	309	328	disease progression	T046	C0242656
27598262	332	357	mild cognitive impairment	T047	C1719378
27598262	359	362	MCI	T047	C1719378
27598262	368	387	Alzheimer's disease	T047	C0002395
27598262	389	391	AD	T047	C0002395
27598262	410	418	patients	T101	C0030705
27598262	424	426	AD	T047	C0002395
27598262	436	439	MCI	T047	C1719378
27598262	455	471	elderly controls	T096	C0009932
27598262	477	488	thicknesses	T080	C1280412
27598262	496	500	RNFL	T023	C1517753
27598262	505	510	GCIPL	T023	C1512785
27598262	529	570	spectral-domain optic coherent tomography	T074	C3876157
27598262	578	590	participants	T098	C0679646
27598262	594	602	baseline	T081	C1442488
27598262	608	616	patients	T101	C0030705
27598262	622	625	MCI	T047	C1719378
27598262	629	631	AD	T047	C0002395
27598262	642	650	clinical	T080	C0205210
27598262	655	679	neuropsychological tests	T060	C0027902
27598262	683	691	baseline	T081	C1442488
27598262	696	734	once every year thereafter for 2 years	T079	C1254367
27598262	740	783	Clinical Dementia Rating scale-Sum of Boxes	T170	C3827230
27598262	785	791	CDR-SB	T170	C3827230
27598262	793	798	score	T081	C0449820
27598262	821	829	negative	T033	C0205160
27598262	830	843	relationships	T080	C0439849
27598262	853	866	average GCIPL	T023	C1512785
27598262	867	876	thickness	T080	C1280412
27598262	907	912	GCIPL	T023	C1512785
27598262	913	922	thickness	T080	C1280412
27598262	930	944	superotemporal	T029	C1275875
27598262	946	957	superonasal	T029	C1275872
27598262	963	982	inferonasal sectors	T029	C1275873
27598262	988	1010	composite memory score	T081	C0449820
27598262	1033	1041	positive	T033	C1446409
27598262	1042	1054	associations	T080	C0439849
27598262	1064	1077	average GCIPL	T023	C1512785
27598262	1078	1087	thickness	T080	C1280412
27598262	1096	1101	GCIPL	T023	C1512785
27598262	1102	1111	thickness	T080	C1280412
27598262	1119	1133	superotemporal	T029	C1275875
27598262	1135	1146	inferonasal	T029	C1275873
27598262	1152	1174	inferotemporal sectors	T029	C1275868
27598262	1180	1193	temporal RNFL	T023	C1517753
27598262	1194	1203	thickness	T080	C1280412
27598262	1229	1234	GCIPL	T023	C1512785
27598262	1235	1246	thicknesses	T080	C1280412
27598262	1256	1261	GCIPL	T023	C1512785
27598262	1262	1271	thickness	T080	C1280412
27598262	1279	1290	inferonasal	T029	C1275873
27598262	1292	1300	inferior	T029	C0005898
27598262	1306	1328	inferotemporal sectors	T029	C1275868
27598262	1332	1340	baseline	T081	C1442488
27598262	1360	1367	reduced	T080	C0392756
27598262	1371	1374	MCI	T047	C1719378
27598262	1375	1383	patients	T101	C0030705
27598262	1406	1408	AD	T047	C0002395
27598262	1428	1431	MCI	T047	C1719378
27598262	1432	1440	patients	T101	C0030705
27598262	1456	1462	CDR-SB	T170	C3827230
27598262	1468	1476	baseline	T081	C1442488
27598262	1482	1487	years	T079	C0439234
27598262	1510	1518	negative	T033	C0205160
27598262	1519	1531	associations	T080	C0439849
27598262	1577	1590	minimum GCIPL	T023	C1512785
27598262	1591	1602	thicknesses	T080	C1280412
27598262	1614	1619	GCIPL	T023	C1512785
27598262	1620	1629	thickness	T080	C1280412
27598262	1637	1651	superotemporal	T029	C1275875
27598262	1653	1661	superior	T029	C0005898
27598262	1663	1674	superonasal	T029	C1275872
27598262	1680	1699	inferonasal sectors	T029	C1275873
27598262	1703	1711	baseline	T081	C1442488
27598262	1743	1748	GCIPL	T023	C1512785
27598262	1749	1758	thickness	T080	C1280412
27598262	1782	1791	biomarker	T201	C0005516
27598262	1811	1822	progression	T046	C0242656
27598262	1826	1829	MCI	T047	C1719378
27598262	1834	1836	AD	T047	C0002395